Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Ethics and Financial Disclosure
One of the most important or core goals of trial registries is transparency within the clinical research process. Transparency is an important goal because of the significance of the objectivity of research, given its role in gaining and maintaining public trust. As a result, several measures have been undertaken by federal regulatory authorities to ensure the objectivity of research, especially in relation to transparency in clinical research process. These measures are also geared towards dealing with increasing complexities of financial interests by various researchers. Actually, objectivity and transparency of research is crucial because of the subsequent interactions among research institutions, the government, and the private sector after a clinical research is carried out.
In light of measures undertaken to promote objectivity and transparency within the clinical research process, federal regulatory agencies have established some rules and regulations that relate to financial interests. One of these regulations is the requirement by federal regulatory authorities that the principal investigator disclose any financial interest in a sponsor company that he/she is carrying out clinical trials for. It is appropriate for federal regulatory authorities to establish the requirement because of the likelihood of any conflicting financial interests on the principal investigator's part. In case the principal investigator...
This in turn helps in enhancing the credibility, objectivity, and transparency within the clinical research process. Through disclosure of such financial interests and arrangements, the principal investigator works with due diligence, which helps in building public trust and the credibility of the research process. Therefore, this requirement by federal regulatory authorities is appropriate with regards to enhancing the objectivity, transparency, and credibility of the clinical trial in a manner that obtains and maintains public trust.
Given the suitability of the requirement of disclosure of financial interests and/or arrangements on the part of the principal investigator in a clinical trial, there are situations where financial disclosure could create a problematic ethical dilemma. When conducting their work, principal investigators in a clinical trial subscribe to three fundamental elements i.e. patient safety, scientific integrity, and investigator objectivity. While scientific integrity and patient safety are important…
References
"Guidance for Clinical Investigators, Industry, and FDA Staff -- Financial Disclosure by Clinical Investigators." (2013, February). Office of Good Clinical Practice. Retrieved from U.S. Department of Health and Human Services -- Food and Drug Administration website: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM341008.pdf
"RCR Conflicts of Interest." (n.d.). Responsible Conduct of Research. Retrieved from Columbia University website: http://ccnmtl.columbia.edu/projects/rcr/rcr_conflicts/foundation/
Regulatory Compliance for Financial Institutions: Implementation of a GLBA-Complaint Information Security Program The objective of this work in writing is to examine the implementation of a GLBA-complaint information security program. Objectives of the Information Security Program The Gramm-Leach-Bliley Act (GLBA) makes a requirement of financial institutions to "develop, implement, and maintain a comprehensive written information security program that protects the privacy and integrity of customer records. GLBA mandates emphasize the need for each
" (Crawford, 2011) These comments are showing how Wellstone understood the risk that this would pose to the financial system. In eight years after making this speech, the federal government would be directly bailing out firms that were too big to fail. This is indicating how the repeal of the Glass Steagall Act allowed financial institutions to engage in excessive amounts of risk taking. It is at this point that they
Because the home country is not required to reimburse foreign depositors for losses, there is no corresponding financial penalty for lax supervision; there is, though, a benefit to the country with lenient regulatory policies because of increased revenues generated and the employment opportunities these services provide (Edwards 1999). Furthermore, banks seeking to conduct multinational business are attracted to countries where incorporation laws and the regulatory framework offer less regulatory oversight
b) It is required that the "summary prospectus appear at the front of a fund's prospectus." (Security Exchange Commission (b)) c) Amendments have been made so that the Internet can be used to give important 'information' inclusive of "description of the fund's investment objectives and strategies, fees, risks, and performance." (Security Exchange Commission (b)) d) The Form N-1A, for mutual funds, should have the "key information at the front of its statutory
Global Financial Crisis Since the early 2008, financial institutions started to go through chaos all over the globe. The stock markets were beginning to crash, businesses were shutting down, and investors were losing their money. This was to indicate that the entire globe had been hit by a period of economic crisis leading to a large number of corporate collapses of banks, investment companies, multinational corporations, etc. This downfall of economic
Consolidation of Financial Statement Analysis In the wake of the Enron collapse, the chairman of the Securities Exchange Commission (SEC) repeated his calls for the nation's securities laws to be updated in an effort to avoid another such case. In an article in December 11, 2001's Wall Street Journal, Harvey Pitt wrote that the Enron collapse underscores the need to update and improve the nation's financial reporting and disclosure laws that